PD-1/LAG-3 bispecific antibody
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PD-1/LAG-3 bispecific antibody, covering 2026-03-18 to 2026-03-18. Get the full timeline:
Most recent: Clinical Trial Update: Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors [Phase 1, Phase 2]